Loss widens at Proximagen on R&D spend 'that should have been higher'
This article was originally published in Scrip
Executive Summary
Neuro-focused drug developer Proximagen reported widened losses in 2010 following a significant increase in R&D spending, which more than doubled to £6.1 million from £2.8 million the previous year. However, Proximagen had initially been prepared to spend much more on R&D during the yeat, CEO Kenneth Mulvany told Scrip.